Malignant Glioma - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Malignant Glioma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H1 2015', provides an overview of the Malignant Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Glioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Glioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Malignant Glioma Overview 8
Therapeutics Development 9
Pipeline Products for Malignant Glioma - Overview 9
Pipeline Products for Malignant Glioma - Comparative Analysis 10
Malignant Glioma - Therapeutics under Development by Companies 11
Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 13
Malignant Glioma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Malignant Glioma - Products under Development by Companies 17
Malignant Glioma - Products under Investigation by Universities/Institutes 18
Malignant Glioma - Companies Involved in Therapeutics Development 19
Advantagene, Inc. 19
Eli Lilly and Company 20
iDD biotech SAS 21
Lipopharma Therapeutics SL 22
Merck & Co., Inc. 23
Nuo Therapeutics, Inc. 24
Orbus Therapeutics, Inc. 25
Sanofi 26
Stemline Therapeutics, Inc. 27
ZIOPHARM Oncology, Inc. 28
Malignant Glioma - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Ad-RTS-IL-12 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALD-451 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Dendritic Cell Therapy for Malignant Gliomas - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dendritic Cell Therapy for Oncology - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Dendritic Cell Therapy for Oncology - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Dendritic Cell Therapy for Oncology - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
eflornithine hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
galunisertib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GliAtak - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IDD-004 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LD-224 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
marizomib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Minerval - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pembrolizumab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SL-701 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Vaccine to Target Survivin for Malignant Glioma - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
voxtalisib - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Malignant Glioma - Recent Pipeline Updates 70
Malignant Glioma - Dormant Projects 84
Malignant Glioma - Discontinued Products 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products under Development for Malignant Glioma, H1 2015 9
Number of Products under Development for Malignant Glioma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Malignant Glioma - Pipeline by Advantagene, Inc., H1 2015 19
Malignant Glioma - Pipeline by Eli Lilly and Company, H1 2015 20
Malignant Glioma - Pipeline by iDD biotech SAS, H1 2015 21
Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H1 2015 22
Malignant Glioma - Pipeline by Merck & Co., Inc., H1 2015 23
Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H1 2015 24
Malignant Glioma - Pipeline by Orbus Therapeutics, Inc., H1 2015 25
Malignant Glioma - Pipeline by Sanofi, H1 2015 26
Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H1 2015 27
Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Malignant Glioma Therapeutics - Recent Pipeline Updates, H1 2015 70
Malignant Glioma - Dormant Projects, H1 2015 84
Malignant Glioma - Discontinued Products, H1 2015 85